Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 6, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	2,322	1,367	775	28	234	377
Market Cap Growth	78.75%	76.31%	2701.10%	-88.19%	-37.90%	70.36%
Enterprise Value	1,837	1,108	959	-41	127	243
Last Close Price	29.96	23.28	21.52	11.25	118.75	196.75
PS Ratio	-	-	874.91	11.88	12.50	-
PB Ratio	6.05	2.64	4.21	0.55	2.79	2.70
P/TBV Ratio	7.76	3.78	-	0.55	2.79	2.70
EV/Sales Ratio	-	-	1082.03	-	6.78	-
Debt / Equity Ratio	-	-	-	0.09	0.07	0.04
Asset Turnover	-	-	0.00	0.03	0.14	-
Quick Ratio	10.59	11.16	10.61	3.83	4.66	8.90
Current Ratio	10.91	11.26	10.68	4.25	4.91	9.11
Return on Equity (ROE)	-38.08%	-59.28%	-289.17%	-124.87%	-58.81%	-80.93%
Return on Assets (ROA)	-30.20%	-27.43%	-35.60%	-58.53%	-30.22%	-41.61%
Return on Capital (ROIC)	-35.73%	-37.15%	-61.52%	-73.41%	-34.95%	-48.37%
Return on Capital Employed (ROCE)	-48.80%	-37.60%	-38.00%	-150.10%	-73.10%	-56.10%
Earnings Yield	-5.10%	-15.22%	-43.70%	-302.87%	-28.09%	-21.44%
FCF Yield	-6.97%	-11.52%	-12.89%	-289.74%	-23.17%	-21.22%
Buyback Yield / Dilution	-59.15%	-581.85%	-104.59%	-28.19%	-23.18%	-67.05%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q